These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28738160)

  • 21. Novel ion channel targets in atrial fibrillation.
    Hancox JC; James AF; Marrion NV; Zhang H; Thomas D
    Expert Opin Ther Targets; 2016 Aug; 20(8):947-58. PubMed ID: 26918581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
    Kiper AK; Rinné S; Rolfes C; Ramírez D; Seebohm G; Netter MF; González W; Decher N
    Pflugers Arch; 2015 May; 467(5):1081-90. PubMed ID: 25511502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel K+ Channel Targets in Atrial Fibrillation Drug Development--Where Are We?
    El-Haou S; Ford JW; Milnes JT
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):412-31. PubMed ID: 25978691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
    Grunnet M; Bentzen BH; Sørensen US; Diness JG
    Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
    Brandts B; Van Bracht M; Dirkmann D; Borchard R; Wickenbrock I; Prull MW; Meine M; Trappe HJ
    Med Klin (Munich); 2004 Jul; 99(7):341-6. PubMed ID: 15322712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the Role of K
    Mondéjar-Parreño G
    Front Biosci (Schol Ed); 2022 Nov; 14(4):31. PubMed ID: 36575841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac K
    Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy.
    Diness JG; Bentzen BH; Sørensen US; Grunnet M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):441-8. PubMed ID: 25830485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
    Brendel J; Peukert S
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):273-87. PubMed ID: 15326917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
    Rinné S; Kiper AK; Schlichthörl G; Dittmann S; Netter MF; Limberg SH; Silbernagel N; Zuzarte M; Moosdorf R; Wulf H; Schulze-Bahr E; Rolfes C; Decher N
    J Mol Cell Cardiol; 2015 Apr; 81():71-80. PubMed ID: 25655935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrium-specific Kir3.x determines inducibility, dynamics, and termination of fibrillation by regulating restitution-driven alternans.
    Bingen BO; Neshati Z; Askar SF; Kazbanov IV; Ypey DL; Panfilov AV; Schalij MJ; de Vries AA; Pijnappels DA
    Circulation; 2013 Dec; 128(25):2732-44. PubMed ID: 24065610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation.
    Diness JG; Sørensen US; Nissen JD; Al-Shahib B; Jespersen T; Grunnet M; Hansen RS
    Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):380-90. PubMed ID: 20562443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atrial-selective drugs for treatment of atrial fibrillation.
    Ravens U; Christ T
    Herzschrittmacherther Elektrophysiol; 2010 Dec; 21(4):217-21. PubMed ID: 21082185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiarrhythmic Effect of Either Negative Modulation or Blockade of Small Conductance Ca2+-activated K+ Channels on Ventricular Fibrillation in Guinea Pig Langendorff-perfused Heart.
    Diness JG; Kirchhoff JE; Sheykhzade M; Jespersen T; Grunnet M
    J Cardiovasc Pharmacol; 2015 Sep; 66(3):294-9. PubMed ID: 25978690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New antiarrhythmic agents in atrial fibrillation].
    Hernández GP; Ortíz PL; López FA; Mondragón Ldel V
    Arch Cardiol Mex; 2007; 77 Suppl 2():S2-59-S2-63. PubMed ID: 17972381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.
    Skibsbye L; Ravens U
    Card Electrophysiol Clin; 2016 Jun; 8(2):395-410. PubMed ID: 27261830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.